Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? Against

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 5, 2003, Pages 776-780

  Goldenberg, David M ^a   Sharkey, Robert M ^a   Karacay, Habibe ^a   McBride, William ^c   Hansen, Hans J ^c   Chang, Chien Hsing ^c   Rossi, Edmund A ^c   Chatal, Jean Francois ^b   Barbet, Jacques ^b  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AVIDIN; BIOTIN; CANCER ANTIBODY; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; HAPTEN; IMMUNOGLOBULIN F(AB) FRAGMENT; INDIUM; IODINE 131; MONOCLONAL ANTIBODY; PENTETIC ACID; RADIOISOTOPE; STREPTAVIDIN;

BINDING AFFINITY; BIOTINYLATION; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; IMMUNOGENICITY; IONIZING RADIATION; METHODOLOGY; MOLECULAR RECOGNITION; NONHODGKIN LYMPHOMA; NONHUMAN; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; REVIEW; SOLID TUMOR; ARTICLE; NEOPLASM; RADIOTHERAPY;

ANTIBODIES, MONOCLONAL; AVIDIN; BIOTIN; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOTHERAPY;

EID: 0141996882     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43:693-713.
2. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 2001; 39:195-201.
3. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-2463.
4. Goodwin DA. Pharmacokinetics and antibodies. J Nucl Med 1987; 28:1358-1362.
5. Goodwin DA. New methods for localizing infection: a role for avidin-biotin? J Nucl Med 1992; 33:1816-1818.
6. Goodwin DA. Tumor pretargeting: almost the bottom line. J Nucl Med 1995; 36:876-879.
7. Lovqvist A, Divgi C. Bullets to magic bullets and miles to go before we sleep. J Nucl Med 1998; 39:1776-1777.
8. Goodwin DA, Meares CF. Pretargeted peptide imaging and therapy. Cance Biotherapy Radiopharmaceuticals 1999; 14:145-152.
9. Le Doussal JM, Barbet J, Delaage M. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental, and clinical results. Int J Cancer (Suppl) 1992; 7:58-62.
10. Chatal, JF, Faivre-Chauvet A, Bardies M, Peltier P, Gautherot E, Barbet J. Bifunctional antibodies for radioimmunotherapy. Hybridoma 1995; 14:125-128.
11. Rosebrough SF. Two-step immunological approaches for imaging and therapy. Q J Nucl Med 1996; 40:234-251.
12. Goodwin DA, Meares CF. Pretargeting: general principles. Cancer (Suppl) 1997; 80:2675-2680.
13. Fritzberg AR. Antibody pretargeted radiotherapy: a new approach and a second chance. J Nucl Med 1998; 39:20N.
14. Barbet J, Kraeber-Bodéré F, Vuillez, JP, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm 1999; 14:153-166.
15. Gruaz-Guyon A, Janevik-Ivanovska E, Raguin O, De Labriolle-Vaylet C, Barbet J. Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy. Q J Nucl Med 2001; 45:201-206.
16. Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, Chatal JF, Barbet J, Goldenberg DM. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther 2002; 1:553-563.
17. Hnatowich DJ, Virzi F, Ruschowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987; 28:1294-1302.
18. Paganelli G, Riva P, Deleide G, Clivio A, Chiolerio F, Scassellati GA, Malcovati M, Siccardi AG. In vivo labeling of biotinylated monoclonal antibodies by radioactive avidin: a strategy to increase tumor radiolocalization. Int J Cancer (Suppl) 1988; 2:121-125.
19. Axworthy DM, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F, Hobson LJ, Beaumier PL, Fritzberg AR. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 2000; 97:1802-1807.
20. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1998; 29:226-234.
21. Goodwin DA, Meares CF, McTigue M, Chaovapong W, Diamanti CI, Ransone CH, McCall MJ. Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J Nucl Med 1992; 33:2006-2013.
22. Rusckowski M, Fritz B, Hnatowich DJ. Localization of infection using straptavidin and biotin: an alternative to nonspecific polyclonal immunoglobulin. J Nucl Med 1992; 33:1810-1815.
23. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989; 30:1358-1366.
24. 111Indium BLEDTA-IV clinical imaging in colorectal carcinoma. Antibody Immunoconjug Radiopharm 1989; 2:1-13.
25. Hosono M, Hosono MN, Kraeber-Bodéré F, Devys A, Thédrez P, Faivre-Chauvet A, Gautherot E, Barbet J, Chatal JF. Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NACM/antihistamine bispecific antibody and radioiodinated bivalent hapten. J Nucl Med 1999; 40:1216-1221.
26. Sharkey RM, Rossi E, Karacay H, McBride W, Chang K, Zeng L, Qu T, Griffiths G, Hansen HJ, Goldenberg DM. A novel recombinant bispecific antibody pretargeting system for cancer radioimmunotherapy [abstract]. Clin Cancer Res (Suppl) 2002; 7:3786s.
27. Kalofonos HP, Rusckowski M, Siebecker DA, Sivolapenko GB, Snook D, Lavender JP, Epenetos AA, Hnatowich DJ. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med 1990; 31:1791-1796.
28. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br J Cancer 2002; 86:207-212.
29. Saga T, Weinstein J N, Jeong JM, Heya T, Le JT, Le N, Paik CH, Sung C, Neumann R. Two-step targeting of experimental lung metastases with biotinylated sntibody and radiolabeled streptavidin. Cancer Res 1994; 54:2160-2165.
30. Wilbur DS, Hamlin DK, Vessella RL, Stray JE, Buhler KR, Stayton PS, Klumb LA, Pathare PM, Weerawarna SA. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin. Bioconjugate Chem 1996; 7:689-702.
31. Kuijpers WHA, Bos ES, Kaspersen FM, Veeneman GH, van Boeckel CAA. Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer. Bioconjugate Chem 1993; 4:94-102.
32. Rusckowski M, Qu T, Chang F, Hnatowich DJ. Pretargeting using peptide nucleic acid. Cancer (Suppl) 1997; 80:2699-2705.
33. Bagshawe KD, Sharma SK, Burke PJ, Melton RG, Knox RJ. Developments with targeted enzymes in cancer therapy. Curr Opin Immunol 1999; 11:579-583.
34. 131I-labeled bivalent hapten, J Nucl Med 2000; 41:480-487.